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ABSTRACT  Platelet-derived  growth factor  (PDGF), a smooth  muscle cell  (SMC) mitogen, and 
heparin-like  glycosaminoglycans, known inhibitors  of SMC growth and migration, were found 
to regulate thrombospondin synthesis and matrix deposition  by cultured  rat aortic SMC. The 
synthesis and  distribution  of  thrombospondin  was  examined  in  growth-arrested  SMCs, in 
PDGF-stimulated  SMCs, and in heparin-treated  SMCs using metabolic  labeling and immuno- 
fluorescence  techniques.  Thrombospondin synthesis in response to purified  PDGF occurred 
within 1 h after addition of growth factor to growth-arrested SMCs, peaked at 2 h, and returned 
to baseline levels by 5 h. The ind0ction of synthesis of thrombospondin  by PDGF was dose 
dependent,  with a maximal effect  observed at 2.5 ng/ml. Actinomycin  D (2 ~,g/ml) inhibited 
thrombospondin induction by PDGF, suggesting a requirement for new RNA synthesis. In the 
presence of heparin  and  related  polyanions,  the  incorporation  of thrombospondin  into the 
SMC  extracellular  matrix  was  markedly  reduced.  This effect  was  dose dependent  with  a 
maximal  effect  observed  at a heparin  concentration  of  1 ~g/ml.  Heparin  did  not affect  the 
ability of SMCs to synthesize thrombospondin in response to PDGF. We interpret  these data 
to suggest a role for thrombospondin  in the SMC proliferative  response to PDGF and in the 
regulation  of SMC growth and migration  by glycosaminoglycans. 
Proliferation of vascular smooth muscle cells (SMCs) j is an 
important component of the atherosclerotic process. Accord- 
ingly, we have begun  studies aimed at achieving an  under- 
standing  of the  molecular basis of SMC  growth regulation, 
with  emphasis  on  the  role  played  by  extracellular  matrix 
(ECM) molecules. The vessel wall contains sources of mole- 
cules stimulatory to  SMCs,  such  as platelet-derived growth 
factor (PDGF) (69),  as well as sources of inhibitory heparin- 
like glycosaminoglycans (GAGs) (3,  4,  7,  20).  Current con- 
cepts of SMC growth regulation in vivo invoke an antagonistic 
interplay between  growth  inhibitors  and  stimulators which 
may determine the extent of SMC response following arterial 
injury (4). 
Heparan sulfate glycosaminoglycans are biosynthetic prod- 
ucts of both vascular endothelial cells (21, 61) and SMCs (21, 
Abbreviations used in this paper.  ECM,  extracellular matrix; EGF, 
epidermal growth factor; FCS, fetal calf  serum; FGF, fibroblast growth 
factor; GAGs, glycosaminoglycans: PDGF,  platelet-derived growth 
factor; PDS, plasma-derived serum: SMC, smooth muscle cell. 
48,  80),  and belong to a  heterogenous family of polyanions 
which can vary greatly in size,  charge density, and sulfation 
(15).  Clowes and  Karnovsky (6)  demonstrated that heparin 
was a potent inhibitor of neointimal SMC growth following 
experimental  arterial  injury  in  the  rat;  the  effect was  not 
related  to  the  anticoagulant  activity  of heparin  (24).  The 
ability of heparin to regulate SMC growth was subsequently 
verified in vitro by several laboratories (3, 4, 26, 28, 58). 
Castellot et al. (3, 4) have shown that conditioned medium 
from cultured endothelium contained a  heparinase-degrada- 
ble activity which was inhibitory to SMC growth in vitro. The 
serum  component  believed  responsible  for  release  of this 
inhibitory activity has been identified as a platelet heparitinase 
(62),  an  enzyme capable  of releasing  free  heparan  sulfate 
GAGs from proteoglycans (60,  62).  Thus  free heparin-like 
GAGs may be present locally in the vascular wall, as recently 
demonstrated by Marcum and Rosenberg (48). These GAGs, 
presumably derived from endothelial cell (3, 4) or SMC (20) 
proteoheparan sulfates, may act as endogenous chalones to 
regulate SMC growth. In addition to their effect on prolifer- 
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of SMC activities, including cellular movement (46), pyrimi- 
dine uptake (8), and biosynthetic phenotype (8, 42-45). 
PDGF was first identified as a serum component released 
from a  granules upon platelet activation (for review see ref- 
erence 69).  PDGF-like proteins are now known  to be pro- 
duced  by  a  variety  of cells  in  culture,  including  vascular 
smooth muscle (75) and endothelial cells (14). The production 
of PDGF-Iike molecules by vascular wall cells may be devel- 
opmentally controlled (75) or activated by arterial injury (19, 
79),  and has been  implicated as a  possible mediator of the 
atherogenic response to injury (67, 68). PDGF has been shown 
to be a primary mitogen for SMCs in culture (5, 57, 70), and 
stimulates pinocytosis (13) and the directed migration of  these 
cells in vitro (23).  The mechanism(s) by which PDGF elicits 
proliferative and migratory responses has not been completely 
elucidated,  but  clearly involves the  induction  of PDGF-re- 
sponsive genes and proteins, at least in embryonic fibroblasts 
(9,  63).  These proteins, termed "competence" proteins (63), 
are believed to function as regulators of early events in the 
cell  cycle, allowing cells to traverse G~  to a  point at which 
they are competent to respond to "progression" factors (for 
review see reference 77). 
In addition  to a  requirement  for specific growth factors, 
cells also require an ECM, appropriate for each particular cell 
type,  for  growth  (33).  Several  studies  have  demonstrated 
alterations in the production of specific ECM components in 
response to growth factors (25,  76,  78),  suggesting that one 
function of growth factors may be to direct the synthesis of 
an ECM appropriate for or facilitative to the optimal growth 
of that particular cell type (73). 
In this report we present data establishing that treatment of 
growth  factor-deprived rat  vascular SMCs  with  nanogram 
amounts of PDGF induces the synthesis of thrombospondin, 
a component of the SMC extracellular matrix (65).  Throm- 
bospondin is an Mr 450,000 glycoprotein first identified as a 
constituent of platelet c~ granules (1) and now known to be 
synthesized and secreted by a variety of cell types in culture 
(30,  51, 52, 65,  71, 72). We also show that SMCs cultured in 
the  presence  of heparin-like  molecules do  not  incorporate 
newly  synthesized  thrombospondin  into  their  ECM.  Thus 
PDGF and heparin antagonistically regulate the production 
of a thrombospondin-rich ECM. These data imply a role for 
thrombospondin in SMC growth and/or migration and in the 
regulation of these processes by GAGs. 
MATERIALS  AND  METHODS 
Cell Culture:  Rat aortic SMC were grown from explants as previously 
described (46). Cells were maintained  in a humidified 37*C/5% CO2 environ- 
ment in Waymouth's medium  supplemented with  10% fetal calf serum (FCS) 
(HyCIone Laboratories, Sterile Systems, Inc., Logan, UT), 100 U/ml penicillin, 
0.1  mg/ml streptomycin,  and 0.4 ug/ml butyl-p-hydroxybenzoate. Cells were 
routinely passaged at a  1:5 split ratio and cultures were used in the second to 
fifth  passage. Growth  factor-deprived  cells were  prepared  by  maintaining 
confluent cultures of SMCs in 20-mm diameter  Costar 6-well plates (Costar, 
Data  Packaging Corp., Cambridge,  MA) in  10%  plasma-derived fetal bovine 
serum (HyCIone Laboratories) for 5-7 d. 
Growth Factors:  Insulin,  epidermal  growth factor (EGF), and  fibro- 
blast growth factor (FGF) were obtained from Collaborative Research (Lexing- 
ton,  MA). Each of the growth factors was tested for mitogenic or mitogenic 
support activity by the manufacturer.  PDGF was obtained from E. Raines and 
R. Ross, University of Washington. and was purified through phenyl sepharose 
as described (64). The PDGF was tested for mitogenic activity on Swiss 3T3 
cells (half-maximal stimulation  of [3H]TdR incorporation  at  1.0 ng/ml) and 
was active in nanogram  amounts in a complementation  test mitogenesis assay 
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using rat aortic SMC (maximal stimulation of DNA synthesis at l0 ng/ml). 
GAGs:  Sodium  heparin  (type  I,  167  USP  U/mg) was obtained  from 
Sigma Chemical Co. (St. Louis, MO). Other heparin preparations with a range 
of anticoagulant  activities (sodium heparin,  158 USP U/mg; RD heparin, Mr 
5,000, 69 USP U/mg; and a hexasaccharide fraction, Mr 2,700, 26 USP U/mg) 
were  provided  by  Hepar  Industries  (Franklin,  OH).  Chondroitin-4-sulfate, 
chondroitin-6-sulfate, and dermatan  sulfate were purchased from Miles Labo- 
ratories,  Inc. (Elkhart,  IN).  Hyaluronic  acid was from  Sigma Chemical  Co. 
Two other heparan sulfate preparations (HSI from bovine liver, and HSI! from 
human aorta) were gifts of Dr. M. H66k, University of Alabama (see reference 
32 for a detailed characterization of HSI and HSII). Unless otherwise indicated, 
experiments were performed with Sigma heparin at  100 ug/ml. 
Analytical Methods:  Metabolic labeling was performed by culturing 
cells with 40-60 uCi/ml [35S]methionine (New England Nuclear, Boston, MA; 
1166.5 Ci/mmol) in  Waymouth's medium  lacking methionine  and  supple- 
mented with antibiotics, 0.1  mg/ml bovine serum albumin (BSA), and growth 
factors or GAGs as indicated. Cells were typically overconfluent at the time of 
the experiment and were labeled for 1 or 2 h at 37"C. 
Metabolically labeled culture medium was harvested into protease inhibitors 
at  4"C, to  produce  a  final concentration  of 0.9  mM  phenylmethylsulfonyl 
fluoride,  1.0 mM N-ethylmaleimide, 23 mM EDTA, and 45 ug/ml pepstatin. 
Cell layers were rinsed three times with phosphate-buffered saline (PBS), then 
lysed  in  0.5  M  NH4OH at  4°C  containing  protease  inhibitors  at  a  final 
concentration  of 0.9 mM phenylmethylsulfonyl fluoride and 45 ug/ml pepsta- 
tin.  Radiolabeled proteins  from medium  and  cell layers were precipitated  in 
10%  trichloroacetic acid, dissolved in SDS PAGE sample buffer as described 
by Laemmli et al. (34), neutralized as required with  1 M NaOH, and resolved 
on 6% or 8% polyacrylamide gels. All gels were run in the presence of 50 mM 
dithiothreitol.  Gels  were  fixed, dried,  and  exposed  to  X-Omat  X-ray  film 
(Eastman Kodak Co., Rochester, NY) at -70°C. Quantitation  of radioactivity 
in protein bands was achieved by densitometric scanning using a Helena Quick- 
Scan densitometer  (Helena Laboratories, Beaumont,  TX). Underexposed gels 
were scanned to insure densitometric  readings in a linear range. 
Radioimmune  precipitation  was performed by harvesting radiolabeled cell 
layer and  medium proteins  into  PBS containing  0.1% SDS and 0.5% Triton 
X-100. Rabbit antisera prepared against human platelet thrombospondin (51, 
65) were used to precipitate  SMC-derived thrombospondin essentially as de- 
scribed by Mumby et al. (54). The human platelet thrombospondin used as 
SDS PAGE standards was prepared as described by Raugi et al. (66). 
Preparation of  Triton X- 100-insoluble "extracellular matrices" was achieved 
by treatment  of metabolically labeled SMC layers with 0.5% Triton  X-100 in 
PBS for 30 min and subsequent washing of  the insoluble residue with PBS (22). 
Treatment  of cell layers in this fashion removed soluble proteins and  mem- 
branes; cell nuclei and cytoskeletons remained  associated with the  insoluble 
ECM. Matrices were prepared for SDS PAGE by addition of sample buffer to 
the culture wells or were used as starting material for the immunoprecipitation 
of thrombospondin as described above. 
lmmunofluorescence  localization of thrombospondin in SMC cultures was 
performed essentially as described by Raugi et al. (65), using anti-thrombo- 
spondin  immunoglobulin  prepared  and  characterized  in this laboratory  and 
used previously for immunolocalization  studies (65, 81). Briefly, SMCs grown 
on glass coverslips were fixed for 5 min in cold (4"C) methanol,  rinsed, and 
exposed to 10% whole sheep serum for 10 min at room temperature. Cells were 
then washed three times in PBS, exposed to rabbit anti-human platelet throm- 
bospondin (l: 10 in PBS) for 30 min at room temperature,  washed again, and 
exposed to FITC-labeled sheep antibodies directed against rabbit IgG (Cappel 
Laboratories, Cochranville,  PA) for 30  min.  Cover slips were then  mounted 
onto slides and photographed on a Zeiss Photomicroscope II. For immunolo- 
calization of fibronectin, goat anti-rat fibronectila (Calbiochem-Behring Corp., 
San Diego, CA), used as a primary antibody, was visualized with rhodamine- 
labeled rabbit anti-goat lgG (Cappel Laboratories). 
RESULTS 
Serum-inducible SIVIC Proteins 
Confluent cultures of rat SMCs were made growth factor- 
deficient by treatment with 0.5% FCS for 72 h, with a serum- 
free defined medium containing transferrin and insulin (41) 
for 72 h, or with 10% plasma-derived serum (PDS) for 5-7 d. 
Subsequent  treatment of cells with  FCS  or purified growth 
factors yielded qualitatively identical results.  All experiments 
described in this paper were performed on cells maintained 
in  10%  PDS.  The  labeling  index  of growth-arrested  cells, following a  30-h exposure to [3H]thymidine and autoradiog- 
raphy, was typically <6%. Stimulation by 10% FCS or 5 ng/ 
ml PDGF (in a complementation test assay containing EGF 
and insulin) increased the labeling index to >80% or >50%, 
respectively. Treatment of growth-arrested SMCs with PDGF 
alone did  not  significantly increase the labeling index,  con- 
sistent  with  the  putative  role of PDGF as a  "competence" 
factor (5, 77). 
To assess the effects of FCS on specific protein induction, 
growth factor--deficient SMCs were treatrd with 10% FCS for 
1 h, then metabolically labeled for 1 h with [3'S]methionine. 
Radiolabeled proteins were resolved on SDS PAGE and vis- 
ualized  by  autoradiography.  Five  cell  layer  proteins  were 
consistently induced by FCS treatment (Fig.  1, lanes 1 and 
2).  Four  of these  proteins  migrated  on  SDS  PAGE  with 
apparent Mr's of 50,000,  55,000,  72,000,  and  110,000.  The 
fifth protein was identified as thrombospondin (Fig.  2).  The 
Mr  55,000  protein  and  thrombospondin were also secreted 
into the culture medium (Fig.  1, lanes 3  and 4).  Other cell 
layer and  secreted  proteins were increased  or decreased in 
individual experiments, but are not detailed here.  It should 
be emphasized that our experimental strategy and gel systems 
were  designed  to  favor the  resolution  of higher  molecular 
weight abundant  proteins induced  as early (within  2  h)  re- 
sponses to growth factors. 
Thrombospondin was identified as a serum-regulated pro- 
tein by the following criteria:  (a) the induced protein chain 
(reduced Mr  150,000-180,000  on  SDS  PAGE) co-migrated 
with human platelet thrombospondin standards under reduc- 
ing (Fig. 2) and nonreducing conditions; (b) the induced band 
was quantitatively  immunoprecipitated using an  antiserum 
prepared against human platelet thrombospondin (Fig.  2) or 
bovine  aortic  endothelial  cell  thrombospondin  (data  not 
shown);  and  (c)  preincubation  of the  antibody with  excess 
human  platelet  thrombospondin  completely prevented  the 
immunoprecipitation of the induced band (data not shown). 
Thus  the  inducible  SMC  Mr  150,000  chain  appears to  be 
electrophoretically and immunologically identical to human 
platelet thrombospondin. 
Effect of Heparin  on Induction of SA4C Proteins 
by Serum 
Since heparin-like molecules are believed to alter SMC gene 
expression and reduce proliferation (see the introduction), we 
asked  if heparin-treated  SMCs  would  respond  less  well  to 
serum  (in  terms of protein  induction)  than  controls.  PDS- 
treated  SMCs  were  exposed  to  100  ~zg/ml heparin  (Sigma 
Chemical Co.) for up to 96  h  in the presence of 10% PDS. 
Cells were then stimulated with FCS and labeled as described 
above; cell layer and secreted proteins were visualized by SDS 
PAGE and  autoradiography.  Heparin treatment had  no in- 
hibitory effect on  the  induction  of SMC  layer or  medium 
proteins by FCS.  Instead, heparin appeared to enhance  the 
secretion of thrombospondin into the culture medium (Fig. 
3, lane 3). Heparin also induced production of two previously 
described proteins (Mr 37,000 and 39,000) (42) in both PDS- 
treated and FCS-stimulated SMCs. 
Effects of Purified Growth Factors on SMC 
Thrombospondin  Synthesis 
To define the  component(s) in  serum  responsible for in- 
duction  of SMC  thrombospondin  synthesis,  we  tested  the 
FIGURE  1  Serum-inducible SMC  proteins. PDS-arrested SMC cul- 
tures  were  labeled for  1  h  with  [3SS]methionine with  or without 
prior exposure for  1  h  to  10%  FCS. Cell  layer (lanes  1 and  2)  or 
medium  (lanes 3  and  4)  proteins  were  harvested  into  protease 
inhibitors and visualized by SDS PAGE (8% gel) and autoradiogra- 
phy. Protein bands indicated at arrows were consistently enhanced 
in FCS-treated cells; their molecular weights (x 10  -3) are indicated. 
One inducible protein was identified as thrombospondin (IS). Both 
thrombospondin and an Mr 55,000 protein (55) were secreted into 
the culture medium. Asterisk indicates the position of migration of 
fibronectin, another SMC  matrix component whose synthesis and 
secretion is unaltered by FCS treatment. 
effects of various purified growth factors on thrombospondin 
production.  PDS-treated  SMCs  were  treated  for  1  h  with 
growth  factor,  then  metabolically  labeled  for  1  h  in  the 
presence  of fresh growth  factor.  Among those  tested,  only 
PDGF was effective in stimulating thrombospondin produc- 
tion, at least within 2 h  (Fig.  4). Other growth factors (5-50 
ng/ml EGF,  100 ng/ml FGF,  1 ug/ml insulin) had no effect 
(data not  shown).  After PDGF treatment, thrombospondin 
production into the culture medium was increased  1.8-3.9- 
fold, as compared with a  1.6-2.3-fold induction by 10% FCS. 
Thus  5  ng/ml of purified  PDGF could  mimic entirely the 
effects of FCS on thrombospondin production.  Because the 
increase in thrombospondin synthesis after PDGF treatment 
could be observed in both cell  layer and medium compart- 
ments (Fig.  4),  in  subsequent  experiments we present only 
data quantifying thrombospondin  levels in  the  culture  me- 
dium. 
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medium following induction by serum. The protein band  labeled 
T5 in Fig. 1 was identified as thrombospondin by its migration  on 
SDS  PAGE and  by  quantitative removal of the  induced  protein 
chain  by immunoprecipitation with anti-human platelet thrombo- 
spondin immunoglobulin. Lane 1, higher molecular weight proteins 
secreted by PDS-treated SMCs; lane 2, induction of an M, 150,000 
protein by  1 h treatment with  FCS; lane 3,  isolation of thrombo- 
spondin from SMC culture medium by immunoprecipitation after 
FCS induction; lane 4,  supernatant  after removal of the induced 
band with antibodies against human platelet thrombospondin. Ar- 
row indicates the position of migration of a human platelet throm- 
bospondin standard. 
Dose Dependence of SMC Thrombospondin 
Induction  by PDGF 
The response of SMC to PDGF was dose dependent within 
a  physiological range.  PDS-treated cells  were exposed to in- 
creasing  amounts  of PDGF  (0.1-5  ng/ml)  for  1  h,  then 
metabolically labeled  for  I  h  in  the  continued  presence of 
PDGF. Secreted radiolabeled proteins were visualized by au- 
toradiogcaphy following SDS PAGE and quantified by scan- 
rang densitometry. Thrombospondin synthesis reached max- 
imal levels at 2.5  ng/mi PDGF, with an EDso at less than  1 
ng/ml PDGF (Fig. 5). Concentrations of PDGF of at least 10 
ng/ml were required to maximally stimulate mitogenesis in 
rat SMCs in a complementation test assay (data not shown). 
Thus induction  by PDGF occurs at levels of growth  factor 
that are suboptimal for proliferation. 
Time Course of Thrombospondin  Production after 
Exposure of SMCs to PDGF 
We next examined PDGF-mediated thrombospondin syn- 
thesis as a function of time. PDS-treated SMCs were treated 
with 5 ng/ml PDGF for 0-8 h, then metabolically labeled for 
1 h in the presence of freshly added PDGF. Secreted proteins 
were visualized by SDS PAGE and autoradiography. As pre- 
sented  in  Fig.  6,  thrombospondin  synthesis in  response to 
PDGF  occurred  rapidly  and  transiently;  labeled  thrombo- 
spondin was observed as a  secreted cell  product within  1 h 
after  stimulation.  Synthesis  of thrombospondin  reached  a 
maximal level after 2 h of PDGF treatment (cells labeled at 1 
h after stimulation) and declined to baseline (PDS) levels by 
5  h.  Thrombospondin  synthesis  remained  low  (and  non- 
inducible) for at least 9 h after the initial addition of PDGF 
(Fig. 6). 
Actinomycin Sensitivity of SMC Thrombospondin 
Induction  by PDGF 
Actinomycin  D,  an  inhibitor  of DNA-dependent  RNA 
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FIGURE 3  Effect of  heparin on  induction  by  serum  of SMC-se- 
creted  proteins.  SMC cultures  were growth arrested  in  10% PDS 
for 5 d in the absence (lanes 1 and 2) or presence (lane 3) of 100 
/~g/ml heparin. Cells were labeled for 1 h with [3~S]methionine with 
or without heparin and with or without prior 1-h exposure to 10% 
FCS. Radiolabeled  secreted proteins were visualized by SDS PAGE 
(10% gel) and autoradiography. Molecular weights (x 10  -3) of FCS 
and heparin-inducible proteins are indicated, as is the position of 
migration  of thrombospondin (TS). Note  that  heparin  does  not 
inhibit the  FCS-mediated induction of thrombospondin or an Mr 
55,000  protein,  but  rather  appears  to  "superinduce"  medium 
thrombospondin synergistically with serum. 
synthesis, was tested for its ability to influence the induction 
of thrombospondin synthesis by PDGF. Addition of 2 ug/ml 
actinomycin to  SMC cultures reduced the synthesis of new 
RNA  (measured  by  [3H]uridine  incorporation  into  total 
RNA) by >  80%  (data not shown).  PDS-treated SMC were 
exposed to actinomycin D  for 30  rain prior to exposure of 
the cells to PDGF. After a  1-h stimulation, cells were meta- 
bolically labeled for  1 h in the presence of fresh PDGF and 
actinomycin. Medium proteins were resolved by SDS PAGE 
and visualized by autoradiography. As shown in Fig. 7, inhi- 
bition  of RNA  synthesis abolished the  ability of PDGF to 
induce thrombospondin synthesis, suggesting  regulation at a 
transcriptional level. 
Analysis of Thrombospondin  Distribution  in 
Control and Heparin-treated 5MC Cultures 
Rat SMC cultures maintained in  10% FCS were metaboli- 
cally labeled for 2 h in the absence or presence of 100 ug/ml 
heparin. Radiolabeled proteins were resolved on SDS PAGE 
followed by autoradiography. As shown in Fig. 8, in heparin- 
treated cell layers the intensity of the thrombospondin band FIGURE  4  Effect of PDGF on cell layer and medium SMC throm- 
bospondin levels.  PDS-arrested SMC cultures were labeled for 1 h 
with [35S]methionine  after a 1-h exposure to 10% FCS (lanes 2 and 
5) or 5 ng/ml PDGF (lanes 3 and 6). In PDGF-treated cells, growth 
factor was present during the  labeling period as well. Cell  layer 
proteins (lanes  1-3) and secreted proteins (lanes 4-6) were visual- 
ized by SDS  PAGE (6% gel) and autoradiography. Note that treat- 
ment of SMCs with  FCS  or  PDGF markedly enhanced thrombo- 
spondin (TS) production in  both cell layer and medium compart- 
ments. Other growth factors had no effect (see text for details). 
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FIGURE  5  Dose dependence of SMC  thrombospondin induction 
by  PDGF.  PDS-arrested  SMCs were  labeled  for  1  h  with  [3ss]- 
methionine in the presence of increasing amounts of PDGF after a 
1-h  pretreatment with  PDGF. Thrombospondin (TS) levels  in  the 
culture medium were determined by quantitative scanning  densi- 
tometry following visualization of radiolabeled secreted proteins by 
SDS  PAGE and  autoradiography. Thrombospondin synthesis  was 
maximal at PDGF concentrations greater than 2.5 ng/ml. 
was markedly reduced (lanes 1 and 2, arrow). Thrombospon- 
din levels were concurrently increased in the medium of cells 
treated with heparin (lanes 3 and 4). 
To verify these observations, we repeated the experiment 
as described above and determined relative thrombospondin 
levels in  SMC  layer and  medium  compartments following 
immunoprecipitation  of SMC  proteins  with  antiserum  to 
human  platelet  thrombospondin.  Imrnunoisolated  proteins 
were resolved by SDS PAGE, visualized by autoradiography, 
then  scanned  with  an  optical densitometer.  Tracings of gel 
scans of the  immunoprecipitated thrombospondin band are 
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FIGURE  6  Time course of thrombospondin production after ex- 
posure of SMCs to PDGF. PDS-arrested SMC cultures were exposed 
to 5 ng/ml PDGF for 0-8 h prior to a  ]-h  metabolic labeling with 
[35S]methionine  in the presence of freshly  added PDGF. Medium 
proteins were visualized by SDS PAGE (6% gel) and autoradiogra- 
phy (top). Thrombospondin (TS) levels were quantified by scanning 
densitometry  (bottom).  Note  that  newly  synthesized  thrombo- 
spondin can be detected in the SMC culture medium within a 1-h 
exposure to PDGF. Thrombospondin production peaks after 2 h of 
exposure and returns to baseline levels by 5 h. 
presented in Fig. 8 (right). These data clearly define the effect 
of heparin  on  SMC  thrombospondin:  in  the  presence  of 
heparin, the distribution of thrombospondin in the culture is 
distinctly shifted into the medium compartment. This obser- 
vation was further verified by the results of a dose-response 
analysis  (see  below).  The  effects  of heparin  appear  to  be 
confined  to  newly synthesized thrombospondin as we were 
unable to release thrombospondin from prelabeled cells with 
heparin treatment (data not shown). 
Dose Dependence of Thrombospondin Release 
from 5MC Layers by Heparin 
A dose-response analysis of  the release of newly synthesized 
thrombospondin from SMC layers was performed by meta- 
bolic labeling of cultures for 2 h in the presence of increasing 
amounts of heparin.  Cell  layer and  medium  proteins were 
At.  Thrombospondin  Synthesis by Vascular  Smooth Muscle Ceils  1063 FIGURE  7  Actinomycin sensitivity of SMC thrombospondin induc- 
tion by PDGF. PDS-arrested SMCs were exposed to 2 #g/ml  acti- 
nomycin D  (lane 3)  for  30  min  prior to the addition of 5 ng/ml 
PDGF (lanes 2 and  3).  Cultures  were then  metabolically labeled 
with  [35S]methionine for 1 h in the absence (lane  1) or presence 
(lane 2) of PDGF and with both PDGF and actinomycin D (lane 3). 
Secreted  proteins  were  visualized  by  SDS  PAGE (6%  gel) and 
autoradiography. Note that actinomycin-treated SMCs do not pro- 
duce thrombospondin (TS)  in response to PDGF (lane 3). 
visualized by SDS PAGE and autoradiography; medium pro- 
teins were quantified by scanning densitometry. Fig. 9 (left) 
presents data on thrombospondin levels in the SMC culture 
medium. Note that a half-maximal response is achieved at a 
heparin concentration of 0.1  ~g/ml, with maximum release 
observed at heparin concentrations greater than  1.0 #g/ml. 
Cell  layer  proteins  from  the  same  experiment are  shown 
resolved by SDS  PAGE  in  Fig.  9  (right).  Note the  strong 
correlation  between  the  dose-dependent  disappearance  of 
thrombospondin from the cell layer and  its increase in  the 
culture medium. 
Analysis of Thrombospondin  in Triton X-100- 
insoluble Cellular Matrices 
To determine if the increased levels of thrombospondin in 
heparin-treated culture medium resulted from an inhibition 
of the interaction of newly synthesized thrombospondin with 
the  SMC  extracellular  matrix,  we  prepared  and  analyzed 
insoluble  SMC  matrices  from  control  and  heparin-treated 
cultures. Confluent cultures of SMCs were treated with  100 
~g/ml heparin for 4 h, then labeled for 2 h with [35S]methio- 
nine. Triton X- 100-insoluble cellular and matrix components 
were resolved by SDS PAGE and autoradiography (Fig. 10A), 
then scanned with an optical densitometer (Fig.  10B). Mat- 
rices prepared from heparin-treated cells contained reduced 
levels of thrombospondin, suggesting  that heparin interferes 
with the initial binding of newly synthesized thrombospondin 
to the SMC extracellular matrix. 
1064  THE  JOURNAL  OF  CELL BIOLOGY  .  VOLUME  101,  1985 
FIGURE 8  Heparin-mediated  release  of  thrombospondin  from 
SMC  layers. Confluent  cultures  of  rat  SMC  were  metabolically 
labeled for 2 h in the absence or presence of 100 #g/ml  heparin. 
Proteins were resolved by SDS PAGE  and visualized by autoradiog- 
raphy.  Lanes 1 and  2,  cell layer proteins;  lanes 3 and  4,  culture 
medium proteins  secreted by SMCs. Arrows  indicate the position 
of  migration of  human  platelet thrombospondin (7-5). Note that 
heparin-treated SMC incorporate less newly synthesized thrombo- 
spondin  into  the  cell  layer compartment and  release increased 
amounts of thrombospondin into the culture medium. This obser- 
vation was verified by  labeling SMC  cultures  for  2  h with  [3sS]- 
methionine in the absence or presence of heparin and quantifying 
the relative amounts  of immunoprecipitated thrombospondin by 
quantitative gel  scanning  densitometry  of  SDS  PAGE autoradi- 
ograms. Gel  scans of thrombospondin immunoprecipitated from 
control (-) and heparin-treated (+) cell layers are shown at upper 
right;  scans of thrombospondin immunoprecipitated from control 
(-)  and  heparin-treated (+)  culture medium are shown  at  lower 
right.  Note that, in the presence of heparin, the majority of newly 
synthesized thrombospondin is found in the culture medium rather 
than associated with the cell layer. 
GAG Specificity of Thrombospondin Release from 
SMC Layers 
Various GAGs were tested for their ability to release newly 
synthesized thrombospondin from SMC layers.  The experi- 
ments were performed by labeling confluent SMC cultures 
for 2  h  with  [35S]methionine  in the presence of 100 ~g/ml 
concentrations  of different GAGs.  Secreted proteins  were 
visualized by autoradiography after SDS PAGE. Only heparin 
and  heparin-like molecules were effective in  increasing the 
amount of thrombospondin released into the medium (Fig. 
I 1). Heparan preparations of differing anticoagulant activities 
(Sigma Chemical Co., 167 USP U/mg; Hepar Industries, 158 
USP U/mg; RD heparin, 69 USP U/mg) were effective, as 
were low molecular weight heparin fragments (Mr 2,700,  26 
USP U/mg) and dermatan sulfate (from porcine skin). Of the 
two different preparations of heparan sulfate GAGs tested, 
only HSI from bovine liver was effective. This heparan sulfate 
binds  to,  and  releases,  endogenous heparan  sulfates  from 
hepatocytes in a concentration-dependent manner (32).  An- 
other heparan  sulfate preparation,  HSII, was  ineffective in 
altering the distribution of thrombospondin within SMC cul- 
tures.  This  molecule does  not  bind  to  hepatocytes and  is 
characterized by a  lower charge density and sulfate content FIGURE 9  Dose dependence of thrombospondin release from SMC layers by heparin. SMC cultures were exposed to increasing 
amounts of heparin during a 2~h metabolic labeling with [3SS]methionine. Proteins were resolved  by SDS PAGE (6% gel) and 
autoradiography. (Left) Quantitation by scanning densitometry of culture medium thrombospondin after the exposure of cells to 
increasing amounts of heparin. Note that maximal release of newly synthesized thrombospondin occurs at heparin concentrations 
greater than 1.0/~g/ml.  (Right)  SDS PAGE autoradiogram of cell layer proteins after the exposure of cells to increasing amounts 
of heparin. Arrow indicates position of migration of human platelet thrombospondin. Note that thrombospondin is not visible in 
the cell layer compartment at heparin concentrations greater than 1.0 ug/ml. 
FIGURE 10  Analysis  of thrombospondin levels  in  Triton  X-100- 
insoluble  cellular matrices. Control or heparin-pretreated  (2 h) SMC 
cultures were labeled for 2 h with [35S]methionine in the presence 
or absence of 100/~g/ml heparin. SMC matrices were prepared by 
exposing SMC layers for 30 min to Triton X-100 as described in the 
text.  (A) Insoluble components of the SMC matrix were visualized 
on SDS PAGE autoradiograms.  The position of migration of immu- 
noprecipitated SMC thrombospondin (TS) is marked with an arrow. 
Lane 1, components of matrices prepared from control SMC; lane 
2, components of matrices prepared from heparin-treated  SMC. (B) 
Tracings of partial gel scans from lanes I and 2 (bar) in A. Note that 
the amount of newly synthesized  thrombospondin present in the 
matrix of heparin-treated SMC is markedly less than that observed 
in control matrices. 
than HSI (32). 
These data suggest that, in addition to polysaccharide con- 
tent,  molecular charge  may  play a  role in  determining  the 
relative activity of the GAG preparations. Other GAGs tested 
(hyaluronic acid,  chondroitin-4-sulfate,  and  chondroitin-6- 
MAJACK  ET  AL. 
FIGURE 11  GAG specificity  of thrombospondin release from SMC 
layers. SMC cultures were metabolically labeled for 2 h with [3sS]- 
methionine in the presence of 100 ~.g/m[ of the appropriate GAG. 
Medium proteins were resolved by SDS PAGE  and autoradiography. 
The position of migration of human platelet thrombospondin ('IS) 
is indicated. Lane 1, medium proteins released from control SMCs. 
Lanes 2-7  show  medium  proteins  secreted  in  the  presence  of 
heparin (lane 2),  "HSI"  (lane 3),  "HSII" (lane 4),  RD heparin  (lane 
5), hexasaccharide (lane 6), and dermatan sulfate (lane 7). See text 
for details. Other GAGs tested (chondroitin-4-sulfate,  chondroitin- 
6-sulfate, and hyaluronic acid) were not effective. 
sulfate) were  not effective.  Thus the range  of GAGs capable 
of altering the distribution of thrombospondin in SMC cul- 
tures is similar to that described for other heparin-mediated 
SMC activities (inhibition of migration, induction of an Mr 
60,000 collagen, and induction of the Mr 37,000 and 39,000 
proteins) (42-46).  Only anticoagulant or non-anticoagulant 
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(42-46). The data emphasize that certain, but not all, heparan 
sulfate GAGs are capable of modifying SMC phenotype. The 
availability of heparan sulfates with (HSI) and without (HSII) 
activity on SMCs may prove useful in efforts to define the 
active moieties responsible for the interactions of heparin-like 
GAGs with SMC. 
Time Course of Activit)/ of Heparin on SMC 
Thrombospondin Distribution 
The time required for heparin to exert an effect on throm- 
bospondin distribution  in SMC cultures was determined by 
treating the cells for increasing amounts of time with 100 #g/ 
ml heparin (0-23 h), labeling the cells for 1 h in the presence 
of heparin, and determining the relative amounts of throm- 
bospondin secreted into the culture  medium. Medium pro- 
teins were resolved by SDS PAGE and autoradiography, then 
quantified  by scanning densitometry.  Thrombospondin  re- 
lease  into  the  medium  compartment  occurred  rapidly  in 
response  to  heparin  and  was  maximal by  4  h  of heparin 
treatment (Fig.  12). 
The duration  of the thrombospondin  effect following re- 
moval of heparin from SMC cultures was also determined. 
SMCs  were  treated  with  heparin  (100  #g/ml)  for  4  h  to 
establish  the  heparin-treated phenotype. Cells were washed 
three times with heparin-free medium and incubated for 0-7 
h in the absence of heparin. Cultures were then metabolically 
labeled for I h with ['S]methionine. Secreted proteins were 
harvested,  visualized by SDS  PAGE  and  autoradiography, 
then quantified by scanning densitometry. After the removal 
of heparin from SMC cultures, levels of radiolabeled throm- 
bospondin  in the medium remained elevated over controls 
FIGURE  12 Time course 
of activity of heparin on 
SMC  thrombospondin 
distribution. (Top) SMC 
cultures  were  labeled 
for 2 h with [3SS]methi- 
onine at  various  inter- 
vals after  the  addition 
of heparin (100  #g/ml) 
to the cultures. Except 
for  control  cultures, 
heparin  was  present 
during the labeling pe- 
riod  as well. The  rela- 
tive amount of throm- 
bospondin  released 
was  determined  by 
scanning  densitometry 
of SOS PAGE autoradi- 
ograms.  Note  that  ex- 
posure of SMCs to hep- 
arin for a minimum of 4 
h  is  required to  maxi- 
mally  release  newly 
g 
0 
o  c 
I- 
E 
"u 
2.0 
1.0 
c  /~  o 
Hours after addition of heparin 
3.0 -@~~ 
2.0 
1.0 
I 
Hours after removal of heparln 
synthesized  thrombospondin into the culture  medium. (Bottom) 
SMC cultures  were pretreated with  100  #g/ml  heparin for 4  h. 
Medium was then replaced with fresh Waymouth's containing no 
heparin.  After specified periods,  cultures  were metabolically la- 
beled with [3SS]methionine and the relative amount of thrombo- 
spondin released was quantified by scanning densitometry of SDS 
PAGE autoradiograms. The heparin effect was completely reversed 
by 8 h after removal of heparin from the culture. 
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for at least 2 h, but were only slightly  increased at 4 h (Fig. 
12). The heparin effect was completely reversible by 8 h. 
fmmunofluorescence  Localization of Fibronectin 
and Thrombospondin in SMC Cultures 
Thrombospondin has been detected previously in matrices 
of human  aortic  SMC  in  vitro (65).  We  have  verified the 
presence of thrombospondin in the rat SMC matrix and have 
examined the distribution of thrombospondin under growth- 
arrested,  PDGF-stimulated,  and heparin-treated conditions. 
Experiments to verify the specificity of the immunolocaliza- 
tion  included  preimmune  and  non-immune  controls  and 
staining with antibody preabsorbed with excess human plate- 
let thrombospondin. SMCs were maintained for 5-7 d in 10% 
PDS, then trypsinized and replated onto sterile glass coverslips 
in the presence of 5% "conditioned" PDS (the original  10% 
PDS was removed, clarified, and diluted  1:1 with fresh Way- 
mouth's medium). This procedure allowed SMCs to be re- 
plated in a growth-arrested state. Thus, the new ECM made 
in the absence or presence of growth factor or heparin could 
be examined. After 24 h of attachment and spreading in 5% 
PDS, cells were left untreated or treated with 5 ng/ml PDGF 
or PDGF plus  100 #g/ml heparin for 24 h.  Cells were then 
permeabilized, fixed, and processed for immunofluorescence 
as detailed above. Cells maintained in PDS exhibited a well- 
developed fibronectin matrix (Fig.  13a), consistent with their 
ability to synthesize and secrete fibronectin under these con- 
ditions (see  Fig.  1).  In contrast,  PDS-treated SMCs did not 
synthesize thrombospondin or incorporate it into the ECM 
(Fig.  13b).  However,  SMC  treated  with  PDGF  for  24  h 
exhibited  both  intracellular  and  extracellular  fluorescence 
when  probed  for thrombospondin (Fig.  13c).  Staining was 
observed in  a  perinuclear pattern (presumably representing 
thrombospondin in Golgi vesicles and secretory granules) as 
well as in a fibrillar extracellular pattern. SMC simultaneously 
exposed to PDGF and heparin exhibited only the perinuclear 
pattern of fluorescence (Fig.  13 d). These observations agree 
with the biochemical data presented above: heparin-treated 
SMCs respond equally well, compared with controls, to PDGF 
but fail to incorporate thrombospondin into their ECM. 
DISCUSSION 
-i-hrombospondin 
Thrombospondin is an Mr 450,000 glycoprotein composed 
of three probably identical disulfide-bonded subunits of Mr 
150,000  (1, 37, 38, 49).  Thrombospondin was first described 
as a component of platelet a-granules (1) and is now known 
to be synthesized by endothelium, fibroblasts, granular pneu- 
mocytes, and smooth muscle cells in culture (30,  51,  52, 65, 
71,  72). While platelet thrombospondin has been assigned a 
role  in  platelet  aggregation  (29,  40)  and,  possibly,  in  the 
binding of platelets to the endothelial  substratum (35,  36), 
the  function of cell-derived thrombospondin is not known. 
Thrombospondin has been shown to interact with collagen 
(36,  53),  heparin (17,  38),  fibrinogen (16),  and  fibronectin 
(35,  36), and to be incorporated into the ECM of fibroblasts 
(30,  65)  and  SMCs  (65).  Thus  thrombospondin  may play 
some, as yet undefined,  role  as a  component of the  SMC 
extracellular matrix. Our data suggest a role for matrix-bound 
thrombospondin in the SMC growth response, presumably as 
an extracellular mediator of some PDGF-regulated function. FJGURE 13  Immunofluorescence localization of fibronectin and thrombospondin in SMC cultures.  PDS-arrested SMC cultures 
were trypsinized and replated onto glass coverslips in conditioned 5% PDS (see text). After 24 h, cells were permeabilized and 
fixed in  absolute methanol and stained,  using specific  antisera, for fibronectin (a) or thrombospondin (b).  Note that growth- 
arrested  SMCs produce an extensive ECM containing fibronectin but not thrombospondin. After exposure of growth-arrested 
SMCs to 5 ng/ml PDGF for 24 h, thrombospondin was located in perinuclear (intracellular)  regions and in a fine fibrillar network 
surrounding the SMCs (c). Treatment of SMCs with  PDGF in the presence  of heparin inhibited the formation of the fibrillar 
thrombospondin network (d); perinuclear staining of thrombospondin remained, x  215. 
Thrombospondin as a PDGF-inducible Protein 
Transient treatment of fibroblasts (77) and porcine smooth 
muscle cells (5)  with PDGF allows the cell to progress to a 
point in G~ in the cell cycle at which additional "progression" 
growth factors are required.  The endowment of PDGF-me- 
diated "competence" to fibroblasts is believed to depend on 
the induction of a family of proteins by PDGF (9, 63). These 
PDGF-inducible  ("competence")  genes  and  proteins  have 
been identified  using metabolic labeling techniques  (63),  in 
vitro translation  of mRNAs extracted from stimulated cells 
(27),  and specific cDNA probes (9,  10,  31).  Several of these 
proteins have been identified  as products of cellular proto- 
oncogenes (10,  31);  at  least three (c-fos,  c-myc, and  an Mr 
29,000  protein) are nuclear in  location (12,  18,  59),  and at 
least one (an Mr 38,000 protein) is secreted (74). 
Little is known concerning PDGF-inducible gene sequences 
from  nonfibroblastic cells.  In  our  studies  of the  effects of 
PDGF  on  smooth  muscle  cell  protein  synthesis,  we  have 
identified at least three major secreted products whose syn- 
thesis is regulated by PDGF.  These proteins, an Mr 25,000 
protein (45),  an Mr 55,000 protein, and thrombospondin, do 
not  appear to be growth factor-regulated proteins in  fibro- 
blasts (56, 63). These data suggest that certain PDGF-induci- 
ble proteins may be cell type specific.  The early induction of 
thrombospondin by PDGF (within  1 h) and the sensitivity of 
the induction to inhibition by actinomycin D raise the possi- 
bility that activation of the thrombospondin gene is a primary 
response of these cells to PDGF. The localization of throm- 
bospondin to the SMC extracellular matrix establishes it as 
unique among known growth factor-inducible proteins and 
supports the concept (see  below) that  ECM molecules may 
play regulatory roles in cellular growth. 
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ECM in SMC Growth 
A variety of studies have established a role for cell-matrix 
interactions in the control of cellular growth (22,  73).  Bitter- 
man et al.  (2) have suggested that fibronectin may facilitate 
competence in fibroblasts. Similarly, type IV collagen mat- 
rices can reduce the requirement of mammary epithelial cells 
for growth factors (73). It has been suggested (39, 73) that one 
function of a growth factor may be to direct the cell's produc- 
tion  of a  growth-supportive ECM.  Specific growth  factors 
have, in fact, been shown to influence production of individ- 
ual matrix components: both FGF and EGF appear to selec- 
tively reduce the production of type I collagen (25,  76,  78), 
while PDGF has been shown to enhance the production of 
type V collagen by fibroblasts (55).  Finally, as shown in this 
study,  vascular SMCs express thrombospondin rapidly and 
transiently after exposure to PDGF. 
The induction of a thrombospondin-rich ECM by PDGF 
suggests that extracellular thrombospondin may play an im- 
portant role in SMC growth and/or migration. In support of 
this concept, we have found that addition of  antibodies against 
thrombospondin to SMC cultures inhibited the migration of 
these cells following experimental wounding (47). Mumby et 
al. (54)  have shown that sparsely cultured,  rapidly growing 
fibroblasts, endothelial cells,  and SMCs synthesized and se- 
creted  higher levels (per cell)  of thrombospondin than  did 
confluent,  more quiescent cultures.  Finally, the immunolo- 
cation of thrombospondin in human aorta is suggestive of a 
growth-related role for matrix thrombospondin. Wight et al. 
(81) found that thrombospondin was located predominantly 
in areas surrounding intimal SMC in sections of atherosele- 
rotic tissue;  thrombospondin was not readily detectable in or 
near SMC in the vascular media. It is likely that intimal SMC 
represent more recently proliferating cells than do their nor- 
mal medial counterparts. 
Heparin Regulation of Thrombospondin 
Deposition  in the Matrix as a Possible Mediator 
of 5MC Growth and/or Migration 
In this report we have shown that heparin-like GAGs inhibit 
the deposition of newly synthesized thrombospondin into the 
SMC extracellular matrix and consequently inhibit the for- 
mation of a  PDGF-inducible, thrombospondin-rich matrix. 
Similarly, McKeown-Longo et al. (50) have recently reported 
that  heparin  inhibits the  binding of radioiodinated  platelet 
thrombospondin to the fibroblast ECM. This heparin effect 
may result from an inhibition of the interaction of thrombo- 
spondin with the cell surface, with type V collagen (53), with 
fibronectin (35,  36),  or with type I  collagen (36),  and may 
involve the heparin binding site in the NH2-terminal region 
of the thrombospondin molecule (11,  17, 66). 
In the experiments presented in this study we have dem- 
onstrated that heparin treatment of SMCs in culture does not 
alter the SMC response to serum factors, at least as judged by 
the induction of  specific proteins, suggesting that heparin does 
not  render  SMCs  unresponsive  to  competence-inducing 
growth factors. However, we have identified an antagonism 
between heparin-like molecules and PDGF in the regulation 
of production of a thrombospondin-rich ECM and speculate 
that such a matrix may be facilitative to SMC growth and/or 
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FIGURE 14  Possible involvement of the ECM in the regulation of 
SMC  growth.  After arterial  injury  or during development, SMCs 
may be transiently  exposed to growth-promoting stimuli,  such as 
PDGF. As shown in this study, PDGF may alter the character of the 
SMC environment by inducing SMCs to produce and incorporate 
thrombospondin (TS) into  their  extracellular matrix  (a). Such  a 
thrombospondin-rich matrix may be facilitative to or required for 
SMC motility and proliferation. Vascular SMCs may also be contin- 
ually exposed to heparin-like GAGs which are normal components 
of the intact vessel wall. These molecules, which are known inhib- 
itors of SMC growth and migration, may exert their effects via direct 
interaction with the SMC surface (b). Alternatively or in addition, 
heparin-like molecules  may exert an indirect effect  on SMCs via 
heparin-mediated (c) or heparin-induced (d) alterations in the ECM 
as indicated on the left. (See References 42 and 43 for additional 
information.) Such alterations, separately or in aggregate, may act 
to inhibit SMC growth and/or migration. 
migration  (Fig.  14). If this  is  true,  then  the  inhibition  of 
thrombospondin deposition by heparin may be a step in the 
mechanism  whereby  heparin-like  molecules  regulate  SMC 
function (Fig.  14). It is possible that thrombospondin may act 
as  an  extracellular  "integrator"  of growth  stimulatory and 
inhibitory signals, since the amount ofthrombospondin func- 
tionally incorporated  into  the  SMC  extracellular  matrix  is 
regulated by both PDGF and heparin-like GAGs. The relative 
amounts of these regulatory signals in the SMC milieu may 
determine, for any vascular injury, the extent of SMC-throm- 
bospondin  interactions  and  consequently the  extent of the 
SMC growth response. We are currently investigating the role 
of thrombospondin in SMC growth and/or migration and in 
the heparin-mediated inhibition of movement and prolifera- 
tion. Taken together, our data on the effects of heparin on 
SMC protein induction and distribution (42-45, this paper) 
strongly reinforce the concept that the character of the ECM 
may be an important determinant of vascular SMC function. 
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